No abstract

Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of ∼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer’s Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company’s ‘lightspeed’ paradigm.

No abstract

No abstract

Taking safety and quality management of power transmission and transformation projects as the main line, this paper studies the practice of construction management of 220kV and above power transmission and transformation projects in Jiangsu province after the system reformation of State Grid Jiangsu Electric Power Company, then refines the experiences and highlights in pre-planning, process management, implementation of management measures and other aspects. The new management mode of power projects with Jiangsu characteristics is established.